
HEPATOTOXICITY;
Author(s) -
Aamna Khokhar,
Aisha Qayyum,
Momina Khokhar
Publication year - 2017
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2017.24.08.957
Subject(s) - medicine , alkaline phosphatase , aspartate transaminase , alanine transaminase , transaminase , alanine aminotransferase , saline , methotrexate , pharmacology , gastroenterology , traditional medicine , enzyme , biochemistry , chemistry
Objectives: To evaluate the protective role of silymarin against methotrexate(MTX) induced hepatotoxicity in mice. Study design: Randomized controlled trial on animalmodel. Period: 06 months from March 2016 to August 2016. Settings: Department ofPharmacology and Therapeutics, Army Medical College, Rawalpindi. Material and Methods:Thirty male BALB/c mice were randomly divided into five groups (n=6). Group A received 0.2 mlnormal saline intraperitoneally served as control for MTX. Group B received 0.2 ml distilled waterorally for 7 days served as control for oral silymarin. Group C received single intraperitonealinjection of MTX 20 mg/kg. Group D received silymarin 25 mg/kg orally for seven days. GroupE received silymarin 25 mg/kg orally for 7 days with MTX 20 mg/kg intraperitoneally at day 4.Blood samples for measuring serum ALT (Alanine Transaminase), AST (Aspartate transaminase)and ALP (Alkaline Phosphatase) along with liver samples for hepatic histological examinationwere taken after 24 hours of last dose. Results: Silymarin show hepatoprotective effect againstMTX induced hepatotoxicity. Conclusion: Silymarin has hepatoprotective potential whenadministered along with MTX.